Macimorelin Acetate
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Macimorelin Acetate |
| DrugBank ID | DB13074 |
| Brand Names (EU) | Ghryvelin (previously Macimorelin Aeterna Zentaris) |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 98.31% |
Approved Indication (EMA)
This medicinal product is for diagnostic use only. GHRYVELIN is indicated for the diagnosis of growth hormone deficiency (GHD) in adults.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | hypertrichosis (disease) | 98.31% | DL |
| 2 | Ambras type hypertrichosis universalis congenita | 97.90% | DL |
| 3 | malformation syndrome with odontal and/or periodontal component | 97.81% | DL |
| 4 | syndrome with a Dandy-Walker malformation as major feature | 97.81% | DL |
| 5 | isolated genetic hair shaft abnormality | 97.67% | DL |
| 6 | allergic urticaria | 93.98% | DL |
| 7 | anomalous left coronary artery from the pulmonary artery | 90.29% | DL |
| 8 | myocardial ischemia | 89.85% | DL |
| 9 | cold urticaria | 89.81% | DL |
| 10 | coronary artery disease | 89.03% | DL |
| 11 | nephrogenic syndrome of inappropriate antidiuresis | 86.98% | DL |
| 12 | familial isolated trichomegaly | 86.81% | DL |
| 13 | mycotic corneal ulcer | 83.42% | DL |
| 14 | papillary conjunctivitis | 80.56% | DL |
| 15 | chronic thromboembolic pulmonary hypertension | 80.37% | DL |
| 16 | recalcitrant atopic dermatitis | 80.25% | DL |
| 17 | uterine polyp | 80.14% | DL |
| 18 | lissencephaly | 80.09% | DL |
| 19 | polyp of vocal cord | 80.04% | DL |
| 20 | polyp of middle ear | 79.87% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.